Tecan reported solid financial results for the first half of 2025, with sales of CHF 439.5 million, a decrease of 3.7% in local currencies. Adjusted EBITDA was CHF 65.7 million, and cash flow increased by 38% year-on-year. The company confirmed its outlook for full-year 2025 and announced a share buyback program.

The Life Sciences Business segment saw sales growth, while the Partnering Business segment experienced a decrease. Tecan strengthened operational resilience through cost-reduction measures and site consolidation. Key product launches in the Life Sciences Business and new partnerships in the Partnering Business were highlighted as well.

Tecan’s CEO Monica Manotas expressed optimism for the company’s growth trajectory, emphasizing innovation, operational improvements, and close customer relationships. The company aims to accelerate growth and remains committed to long-term success.

Tecan also announced the launch of a share buyback program, demonstrating confidence in its financial position and growth prospects. The buyback program will repurchase up to CHF 120 million worth of registered shares, equivalent to 6.01% of the share capital.

Looking ahead, Tecan confirmed its full-year sales outlook and adjusted EBITDA margin forecast for 2025. The company anticipates a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies in the mid-term.

Tecan’s commitment to investing in growth and M&A remains strong, with a focus on organic expansion and maintaining a solid investment grade rating. The company will provide a Q3 Qualitative Update on October 13, 2025, to keep shareholders informed of its progress.

Read more at GlobeNewswire: Tecan reports solid financial results for the first half of